FDA granted Breakthrough Therapy Designation to Ziftomenib and entered a global strategic collaboration agreement.
4 reports, 1 independent
Updated Aug 5
Gone quiet
- Reports
- 4
- Developments
- 3
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted Breakthrough Therapy Designation to Ziftomenib and entered a global strategic collaboration agreement.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- The FDA has selected a facility for a PreCheck Pilot Program involving Kyowa Kirin.Sub-event
FDA granted Breakthrough Therapy Designation to Ziftomenib, involving Kura Oncology and Kyowa Kirin.1 source
- FDA accepted the NDA for ziftomenib, advancing the drug's approval process.
Keep exploring
The entities involved
- FDA
-
Kura Oncology
company in La Jolla, United States
Nothing else this week.
-
Kyowa Kirin
pharmaceutical company
Nothing else this week.
Related events
- Zenith collaborates with Harvard researchers on clinical studies, receiving FDA clearance for the trial.
- FDA approval expands patient access to therapies for ACCORD.
- Research advances have led to the approval of new therapies by the FDA.
- Arcutis Biotherapeutics submitted a supplemental New Drug Application (sNDA) to the FDA to expand the indication for its drug ZORYVE.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
Coverage
Newest first; wire copies grouped- GlobeNewswireKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharm
- GlobeNewswireKura Oncology to Report Second Quarter 2025 Financial Results SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to
- Unknown outlet